Project Grant R01AI179890

Award Date 6/13/24
Completion Date 4/30/29
Dollars Obligated $2.3M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research into the role of cell-to-cell transmission in alphavirus infection and disease. The total award is $506,530.00 with a project period from November 20, 2024 to October 31, 2026. The key objectives of this research are to: 1) determine the mechanisms by which antibodies can block alphavirus cell-to-cell...
The Applied Research Foundation of West Virginia received a $444,000 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research program) to study the effects of stress on Chlamydia infections in a mouse model. The research aims to define the mechanisms by which stress may suppress the immune system and increase the intensity of Chlamydia genital infection and its associated immunopathologies. Key aspects of the project...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $147,656 to the University of Colorado-Denver to conduct research aimed at elucidating the mechanisms that drive the development of chronic Chikungunya virus (CHIKV) arthritis. The research project seeks to define a viral reservoir in macrophages, assess mechanisms that drive pro-inflammatory programming in...
This Project Grant award from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to develop novel hamster models of Chikungunya virus (CHIKV) infection and associated chronic arthralgia. The total award amount is $915,178, covering the project period from July 5, 2024 to May 31, 2026. The research aims to understand the roles of type I and III interferons...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $502,248 in funding to the University of Florida to investigate how human intestinal epithelial cells produce type III interferons to combat rotavirus infection. The key products or services to be delivered under this 5-year award include: 1) Determining how the STING pathway senses rotavirus infection and...
This Project Grant award, valued at $2,370,939.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to define the molecular mechanisms by which the Chikungunya virus (CHIKV) binds to heparan sulfate on target cells, and how these virus-host interactions influence viral tropism, infectivity, and pathogenesis. The research aims to elucidate the structural...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a 2-year, $544,500 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the Texas Biomedical Research Institute to characterize a novel mouse model for studying the neurological impacts of Chikungunya virus infection. The research aims to determine the mechanisms by which Chikungunya virus infects the brain and evaluate whether the mouse model develops the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $843,620 to Albert Einstein College of Medicine for the development of broadly inhibitory antibody therapies against Chikungunya virus (CHIKV) and other arthritogenic alphaviruses. The objectives are to: (1) engineer Fc mutations into broadly protective antibodies to enhance their in vitro and in vivo properties;...
This $769,115 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to advance the understanding of how neurotropic viruses, including flaviviruses and alphaviruses, can directly enter the central nervous system (CNS) through newly described meningeal structures called arachnoid cuff exit (ACE) points. The research team from The Washington University in St. Louis will...
This $290,132 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to define how the cellular protein SLBP (stem-loop binding protein) promotes the infectivity of human cytomegalovirus (HCMV). The overarching goal is to identify and characterize this novel, pro-viral function of SLBP during HCMV infection. The research will determine the specific SLBP function required to promote HCMV infectivity,...

DETERMINING THE IMPACT OF STROMAL CELL-MEDIATED TYPE I IFN SIGNALING ON ALPHAVIRUS PATHOGENESIS - ABSTRACT TYPE I INTERFERONS (IFNS) ARE IMPORTANT INNATE CYTOKINES THAT INFLUENCE LOCAL AND SYSTEMIC IMMUNE RESPONSES. THEY CAN PLAY BENEFICIAL ROLES THROUGH THEIR ANTIVIRAL PROPERTIES AND ABILITY TO AUGMENT HOST IMMUNE RESPONSES; HOWEVER, IFN RESPONSES CAN ALSO HAVE DETRIMENTAL OUTCOMES FOR THE HOST. THE FACTORS THAT DETERMINE THESE DIFFERENTIAL OUTCOMES ARE POORLY UNDERSTOOD. CHIKUNGUNYA VIRUS (CHIKV) IS A RE-EMERGING ALPHAVIRUS THAT CAUSES SEVERE, FEBRILE ARTHRITIS AND MYOSITIS. TYPE I IFNS ARE A KEY HOST RESPONSE DURING ALPHAVIRUS INFECTION. MICE LACKING THE TYPE I IFN RECEPTOR DEVELOP SEVERE AND RAPIDLY FATAL DISEASE FOLLOWING INFECTION WITH CHIKV OR OTHER ALPHAVIRUSES. IN STUDYING THIS RESPONSE, WE HAVE MADE SEVERAL INTERESTING OBSERVATIONS. FIRST, IFNS EXERT BOTH BENEFICIAL AND DETRIMENTAL EFFECTS DURING CHIKV INFECTION. SECOND, IFNS REGULATE THE HOST RESPONSE TO CHIVK BY SIGNALING ON NON-HEMATOPOIETIC CELLS, LIKELY STROMAL CELLS AND OTHER STRUCTURAL CELLS SUCH AS FIBROBLASTS AND ENDOTHELIAL CELLS. THE CONTRIBUTION OF STROMAL CELLS TO IN VIVO HOST IMMUNE RESPONSES REMAINS POORLY DEFINED, EVEN THOUGH THESE CELL TYPES ARE AMONG THE FIRST CELLS TO RESPOND TO VACCINATIONS AND VECTOR-BORNE INFECTIOUS DISEASES. OUR PROPOSED RESEARCH WILL TEST THE HYPOTHESIS THAT TYPE I IFNS PLAY DISTINCT ROLES THROUGHOUT THE COURSE OF CHIKV INFECTION DUE TO THE RESPONSES OF DISTINCT STROMAL CELL POPULATIONS. THE STUDIES PROPOSED WILL UTILIZE MOUSE GENETICS TO CONDITIONALLY DELETE IFN SIGNALING FROM DIFFERENT STROMAL CELLS, TEMPORAL ANTIBODY BLOCKING STRATEGIES, AND RNA SEQUENCING TECHNIQUES TO INTERROGATE HOW IFNS IMPACT THESE SPECIFIC CELLS AT DIFFERENT TIMES DURING CHIKV INFECTION. THESE FINDINGS HAVE THE POTENTIAL TO GREATLY EXPAND OUR UNDERSTANDING OF STROMAL CELLS IFN RESPONSES AND HOW THESE CELLS CONTRIBUTE TO SHAPING THE TISSUE-SPECIFIC IMMUNE RESPONSE DURING INFECTIONS AND VACCINATIONS.

Posted 6/13/24, 12:00 AM